PMID- 32185544
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1437-7799 (Electronic)
IS  - 1342-1751 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Jul
TI  - Early responsiveness to continuous erythropoietin receptor activator predicts 
      renal prognosis and is determined by a novel antioxidative marker in non-dialysis 
      chronic kidney disease: a prospective, observational, single-center study.
PG  - 590-597
LID - 10.1007/s10157-020-01873-0 [doi]
AB  - BACKGROUND: Responsiveness to erythropoietin-stimulating agents (ESAs) is 
      important for anemia management in chronic kidney disease (CKD). We assessed the 
      effects of a continuous erythropoietin receptor activator (CERA) on 
      renoprotection beyond anemia management and the correlation between the 
      responsiveness to ESAs and oxidative stress markers in CKD. METHODS: This 
      single-center, prospective, observational study was conducted over 24 months. We 
      administered CERA to 35 non-dialysis patients with hemoglobin (Hb) < 11 g/dL and 
      examined the results of the serum diacron-reactive oxygen metabolite (dROMs) test 
      for oxidative stress markers and biological antioxidant potential (BAP) test for 
      antioxidant markers. We then examined the renoprotective effects of CERA and the 
      responsiveness to CERA. RESULTS: Eighteen patients experienced renal events 
      (doubling of serum creatinine levels, decreased estimated glomerular filtration 
      rate to < 6.0 mL/min/1.73 m(2), or initiation of renal replacement therapy), 
      seventeen of which survived. Kaplan-Meier analysis showed that responsiveness to 
      CERA during the initial 3-month treatment period was a good predictor of renal 
      events. Moreover, a high response to CERA during the 3 months independently 
      suppressed renal events (hazard ratio, 0.344). High BAP levels at baseline were 
      significantly associated with high responsiveness to CERA during the initial 
      3-month treatment period. CONCLUSION: Responsiveness to CERA during the first 
      3 months was an important indicator of CKD progression. Moreover, BAP test 
      results determined responsiveness to CERA. This is the first report to show how 
      antioxidant levels can be a potential marker of CERA's ability to control anemia 
      in CKD patients.
FAU - Ino, Jun
AU  - Ino J
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan. pikkun46@hotmail.com.
FAU - Kasama, Eri
AU  - Kasama E
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Kodama, Mio
AU  - Kodama M
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Harada, Takako
AU  - Harada T
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Sato, Keitaro
AU  - Sato K
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Eizumi, Hitoshi
AU  - Eizumi H
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Kawashima, Youichiro
AU  - Kawashima Y
AD  - Department of Nephrology, Toda Central General Hospital, 1-19-3 Hon-cho, Toda 
      city, Saitama, 335-0023, Japan.
FAU - Nitta, Kosaku
AU  - Nitta K
AD  - Department of Internal Medicine IV, Tokyo Women's Medical University, 8-1 
      Kawada-cho, Shinjyuku-ku, Tokyo, 162-0054, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200317
PL  - Japan
TA  - Clin Exp Nephrol
JT  - Clinical and experimental nephrology
JID - 9709923
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Hematinics)
RN  - 0 (Hemoglobins)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (continuous erythropoietin receptor activator)
RN  - 11096-26-7 (Erythropoietin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/*drug therapy/etiology
MH  - Antioxidants/*metabolism
MH  - Biomarkers/blood
MH  - Creatinine/blood
MH  - Disease Progression
MH  - Erythropoietin/administration & dosage/*therapeutic use
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hematinics/administration & dosage/*therapeutic use
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress
MH  - Polyethylene Glycols/administration & dosage/*therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Reactive Oxygen Species/*blood
MH  - Renal Insufficiency/complications/*physiopathology/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Continuous erythropoietin receptor activator
OT  - Oxidative stress
OT  - Renal anemia
EDAT- 2020/03/19 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/03/19 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/03/19 06:00 [entrez]
AID - 10.1007/s10157-020-01873-0 [pii]
AID - 10.1007/s10157-020-01873-0 [doi]
PST - ppublish
SO  - Clin Exp Nephrol. 2020 Jul;24(7):590-597. doi: 10.1007/s10157-020-01873-0. Epub 
      2020 Mar 17.